Cantitate/Preț
Produs
Total produse
Vezi coșul
Evolution-adjusted Tumor Pathophysiology: de Albrecht Reichle

Evolution-adjusted Tumor Pathophysiology:

Editat de Albrecht Reichle
en Limba Engleză Hardback – 11 iul 2013
Combined modularized therapies for metastatic cancer are pointing to central problems of communication among ‘systems participators’. A communication theory explains 'social engineering', endogenously induced or by implementing non-normative boundary conditions. Evolution-adjusted tumor pathophysiology is borne by an evolution theory, which contrasts narrative evolution histories. The tool of rationalizations constituting the tumor's normativity (inflammation, immune response etc.) represents the non-genomic counterpart of the tumor genome and should be additionally assessed during tumor staging. Evolution-adjusted tumor pathophysiology allows implementing applied systems biology, a novel clinical and pharmaceutical technology for bioengineering tumor response and personalizing tumor therapy. Combined modularized therapy, evolution-adjusted tumor pathophysiology, and ‘universal’ biomarkers concertedly address genetically based tumor heterogeneity.
Citește tot Restrânge

Preț: 107215 lei

Preț vechi: 112858 lei
-5%

Puncte Express: 1608
Paperback 106055 lei
Hardback 107215 lei

Carte tipărită la comandă

Livrare economică 24 iulie-07 august

Livrare prin curier în România Termenul estimat este afișat lângă disponibilitate.
Transport gratuit pentru acest produs Plată online sau ramburs, în funcție de opțiunile comenzii.
Retur gratuit în 14 zile Comandă securizată și suport în română.
 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă

Specificații

ISBN-13: 9789400768659
ISBN-10: 9400768656
Pagini: 464
Ilustrații: X, 453 p.
Dimensiuni: 160 x 241 x 30 mm
Greutate: 0.86 kg
Ediția:2013
Editura: Springer
Locul publicării:Dordrecht, Netherlands

Public țintă

Professional/practitioner

Cuprins

Preface.-I Introduction.-Communication ─ evolution ─ pathophysiology: An endogenous conjunction ─Instead of an introduction.-II Combined modularized therapies for metastatic tumors: Pointing to central problems of communication among ‘systems participators’ in tumors.- Applied systems biology for the control of metastatic cancer: Therapeutic top-down strategy for targeting the tumors’ normativity.- Targeting the proangiogenic network in angiosarcomas: Biomodulatory therapy.- Long-term results of combined modularized, immune-modulatory, angiostatic, and antiinflammatory therapy in systemically pre-treated multi-systems Langerhans cell histiocytosis.- Redirecting and modulating rationalizations of tumor-immanent normative functions in castration-resistant prostate ancer.-III Social engineering: Biomodulation, either endogenously initiated or by implementation of non-normative boundary conditions.- Non-hierarchically organized operations in malignancies: Stromal dysfunction induces hematopoetic malignancies.- Biomodulatory therapy approaches in renal clear cell carcinoma: A perspective.- Proteome analysis identified the PPARc ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.IV   The tumors’ normativity: Reconstructing and operationalizing starting  points for an evolution theory.- The philosophical quest of a cancer cell: Redefining existentialism.- The tumor’s normativity: Normative structures, action norms and decision maxims as therapeutic targets for tumor therapy.- Criticizable claims for the validity of communication acts in biological systems: Therapeutic implications in cancer.-V Evolution theory.- Evolution theory: Its practical relevance for understanding tumor development and specifying tumor therapy.- Modularity, subjectivity, intersubjectivity and normativity: Clinically applicable operative benchmarks.- Turningupside down the mode of science to emphasize and harness the impact of environmental communicative events. VI   From genome- or organ-centric to rationalization-centric systematization of tumors.- Purposive-rational tumor therapy: Exploiting the tumor’s ‘living world’ for diversifying, specifying and personalizing tumor therapy.- Including rationalizations of tumor-associated normative notions in pathophysiologic considerations: Communication-theoretical implications.-VII  Reconstruction of tumor-immanent normative functions, structures and decision maxims (hubs).- Bridging a diagnostic and therapeutic gap: Selecting, assessing and categorizing tumor-associated normative notions.- Personalizing tumor pathophysiology by diagnosing developmental problems in tumors with imaging techniques.- Biologic memory: Induction by metronomically administered combined modularized therapy.- VIII The tool of rationalizations constituting tumor-associated normative notions: The non-genomic counterpart of the tumor genome and therefore, an important therapeutic target for diversifying palliative care.- Diversifying and specifying palliative care for patients with metastatic cancer by therapeutic implementation of non-normative boundary conditions.- Targeting a hallmark of cancer: Simultaneous inflammation and tumor control for palliative care in metastatic cancer.-IX  Novel clinical and pharmaceutical technology for bioengineering tumor response.- Combined modularized tumor therapy ─ tumor biology ─ and prognostic factors: Bioengineering tumor response.-X Objectifying the systems objects’ subjectivity in biological systems: A novel reification of the scientific picture about the ‘objective’ world.- The systems objects’ subjectivity as scientific object. Index.

Textul de pe ultima copertă

Combined modularized therapies for metastatic cancer are pointing to central problems of communication among ‘systems participators’. A communication theory explains 'social engineering', endogenously induced or by implementing non-normative boundary conditions. Evolution-adjusted tumor pathophysiology is borne by an evolution theory, which contrasts narrative evolution histories. The tool of rationalizations constituting the tumor's normativity (inflammation, immune response etc.) represents the non-genomic counterpart of the tumor genome and should be additionally assessed during tumor staging. Evolution-adjusted tumor pathophysiology allows implementing applied systems biology, a novel clinical and pharmaceutical technology for bioengineering tumor response and personalizing tumor therapy. Combined modularized therapy, evolution-adjusted tumor pathophysiology, and ‘universal’ biomarkers concertedly address genetically based tumor heterogeneity.

Caracteristici

Applied systems biology Personalizing tumor therapy with novel methodological approaches Drafting the non-genomic counterpart of the genome: Rationalizations constituting tumor-associated normative notions (angiogenesis, inflammation, immune response etc.) Reconstructing and operationalizing starting points for an evolution theory Evolution-adjusted tumor pathophysiology as novel clinical and pharmaceutical technology for bioengineering tumor response